VERAXA Biotech (NASDAQ: VRXA) announced on July 27, 2026, that its bispecific antibody-drug conjugate (bsADC) program, VXA-222, has reached a key technical milestone in its collaboration with OmniAb. OmniAb has successfully completed its discovery work, allowing the program to move into its next phase. VXA-222 is designed to target two tumor antigens with a single molecule using an “AND-gate” approach intended to improve precision in treating solid tumors.
Under the collaboration launched in May 2025, OmniAb provided antibody discovery technologies, including its OmniClic(TM) platform, while VERAXA is applying its proprietary linker technology and conjugation expertise to develop and validate the lead bsADC candidate. VERAXA holds exclusive rights to develop and commercialize products arising from the collaboration, with OmniAb entitled to a share of specified revenue generated from resulting products. This milestone is important because it validates the collaboration's progress and brings VERAXA closer to potentially delivering a novel therapeutic option for solid tumors.
The advancement of VXA-222 underscores VERAXA’s commitment to building a premier engine for next-generation antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL) and is guided by rigorous quality-by-design principles. For more details, the full press release is available at https://ibn.fm/qMRuJ.
This development also highlights the potential of the BiTAC(R) platform, a registered trademark of VERAXA Biotech GmbH, which is being rapidly advanced into clinical development. Investors and stakeholders should note that forward-looking statements in this article involve risks and uncertainties detailed in the company's SEC filings. The latest news and updates relating to VRXA can be found at https://ibn.fm/VRXA.
